Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | MYB | P10242 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269926 | 0.87 | MAPT (0.57) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL3274613 | 0.80 | MAPT (0.62) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL16309563 | 0.76 | MAPT (0.46) | MAPTCYP1A2CYP2C9CYP2C19MYB | |
| SCHEMBL16309559 | 0.76 | IRAK4 (0.49) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL16309562 | 0.73 | MAPT (0.71) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL16241795 | 0.73 | MAPT (0.54) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL27740253 | 0.72 | MAPT (0.60) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL19222664 | 0.72 | MAPT (0.53) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL27740254 | 0.71 | MAPT (0.47) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL30719117 | 0.71 | MAPT (0.55) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414833-B1 | NOVEL TRANSITION-METAL COMPLEXES AND USE THEREOF IN TRANSITION-METAL CATALYSED REACTIONS | SALTIGO GMBH (DE) | 2010-06-16 | — | — | EP | claimed |
| EP-1414833-B1 | NOVEL TRANSITION-METAL COMPLEXES AND USE THEREOF IN TRANSITION-METAL CATALYSED REACTIONS | SALTIGO GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20040176608-A1 | Novel transition-metal complexes and use thereof in transition-metal catalyzed reactions | BAYER CHEMICALS AG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-1414833-A1 | NOVEL TRANSITION-METAL COMPLEXES AND USE THEREOF IN TRANSITION-METAL CATALYSED REACTIONS | Bayer Chemicals AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011875-A1 | NOVEL TRANSITION-METAL COMPLEXES AND USE THEREOF IN TRANSITION-METAL CATALYSED REACTIONS | BAYER CHEMICALS AG (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176608-A1 | Novel transition-metal complexes and use thereof in transition-metal catalyzed reactions | AP1M1, SOD1, INTS9 | MAPT 2516/4885CYP1A2 133/4885CYP2C9 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.